Blood pressure control in patients with uncontrolled hypertension by switching from the mono - or combined therapy to the fixed combination of angiotensin II converting enzyme inhibitor and calcium blocker
https://doi.org/10.18705/1607-419X-2012-18-6-484-490
Abstract
Objective. The paper presents the results of the blood pressure (BP) control by switching from unsuccessful monotherapy and combination therapy to fixed combination «perindopril/amlodipine» in the routine practice. Design and methods. PRORYV (BREAK) program included 589 outpatient general practitioners (GPs) and cardiologists from medical and preventive institutions in 50 Russian cities and 4 115 patients with uncontrolled hypertension (HT). PRORYV is an open, multicentered, observational non-comparative study. Inefficient anti-HT therapy (except for treatment with beta-blockers) was cancelled. Results. With fixed-dose combination therapy perindopril/amlodipine BP level lowered from 167,1/97,6 to 130/80,1 mm Hg (by 37,1/17,5 mm Hg) on average in all patients, and the effect was comparable in both males and females, regardless age, coronary artery disease or diabetes. Target BP was achieved in 80 % patients. Results. Switching to fixed-dose combination perindopril/amlodipine (Prestance, Servier, France) from mono- or combination therapy leads to fast and persistent anti-HT effect in all patients with previously uncontrolled BP.
About the Author
Y. A. Karpov
Federal State Budget Institution «Russian Cardiology Scientific and Industrial Complex»
Russian Federation
Russian Federation
References
1. Российское медицинское общество по артериальной гипертонии (РМОАГ), Всероссийское научное общество кардиологов (ВНОК). Диагностика и лечение артериальной гипертензии. Российские рекомендации (четвертый пересмотр) // Системные гипертензии. – 2010. - № 3. – С. 5-26.
2. The Task Force for the management of arterial hypertension of the European Society of Hypertension and of the European Society of Cardiology. 2007 Guidelines for the management of arterial hypertension // J. Hypertens. – 2007. – Vol. 25, № 6. – P. 1105-1187.
3. Mancia G., Laurent S., Agabiti-Rosei E. et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document // J. Hypertens. – 2009. – Vol. 27, № 11. – P. 2121-2158.
4. Оганов Р.Г., Тимофеева Т.Н., Колтунов И.Е. и др. Эпидемиология артериальной гипертонии в России. Результаты федерального мониторинга 2003-2010 гг. // Кардиоваск. терапия и профилактика. – 2011. – Т. 10, № 1. – С. 8-12.
5. Jamerson K.A., Weber M.A., Bakris G.L. et al. on behalf of the ACCOMPLISH investigators. Benazepril plus amlodipine or hydrochlorotiazide for hypertension in high-risk patients // N. Engl. J. Med. – 2008. – Vol. 359, № 23. – P. 2417-2428.
6. Карпов Ю.А., Деев А.Д. от имени врачей-участников программы ПРОРЫВ. Неконтролируемая АГ – новые возможности в решении проблемы повышения эффективности лечения // Кардиология. – 2012. - № 2. – С. 29-35.
7. Girish M.P., Bahl V., Jadhav U., Thacker H., Kumar S. Blood pressure control of fixed dose, perindopril/amlodipine combination treatment in hypertensive patients uncontrolled on monotherapy or on two drug combination therapy // J. Hypertens. – 2010. – Vol. 28, e-suppl. A. – P. e98 [Abstract].
8. Julius S., Kjeldsen S.E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipin: the VALUE randomised trial // Lancet. – 2004. – Vol. 363, № 9426. – P. 2021-2031.
Review
For citations:
Karpov Y.A. Blood pressure control in patients with uncontrolled hypertension by switching from the mono - or combined therapy to the fixed combination of angiotensin II converting enzyme inhibitor and calcium blocker. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(6):484-490. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-6-484-490
Views:
1010
Email this article 